Hospital do Cancer III - INCA / Instituto Nacional do Cancer / MS INCA HCIII

Rio de Janeiro, Rio de Janeiro 20560-120

0 studies enrolling now · 1 studies all time

What they study most

BRCA 1 Gene Mutation, BRCA 2 Gene Mutation, Breast Neoplasms

Studies at this site

• A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) — Completed